CU Boulder Startups in the News

Arpeggio’s technology isolates a drug’s effect on entire transcriptomes and has identified new modulators of hard-to-drug proteins like transcription factors. Funding was led by Builders VC and will support ongoing development of Arpeggio’s drug pipeline as well as its transcription-monitoring technologies.

This year’s Top Company winners and finalists represent 13 industry categories. Entrants were judged on three criteria: outstanding achievement, financial performance and community involvement. ColdQuanta won in the "Technology, Software & Communications" category.

It's hard to find a physics or chemistry teacher that doesn't use PhET Interactive Simulations, a free online science and math simulations platform founded at CU Boulder in 2002 by Nobel Laureate Carl Wieman. These beautifully designed STEM explorations are loved by students and educators alike.

Keith “Bang Bang” McCurdy is taking HYPRSKN—the microscopic skin implants with adaptive, color-changing in-skin pigments developed by Carson Bruns and Jesse Butterfield of CU Boulder's ATLAS Institute—to the next level with real tattoo ink that you can “turn on” or off using different wavelengths of UV and white light.

The merger is addressing pressing needs in quantum research for CU Boulder spinout ColdQuanta—as well as the quantum industry. Both companies are affiliates of Q-NEXT, a U.S. Department of Energy (DOE) National Quantum Information Science Research Center led by Argonne National Laboratory.

Think Bioscience (“Think”), a synthetic biology company focused on developing small-molecule therapeutics that target difficult-to-drug proteins, has raised $17M in an oversubscribed Seed round. Think's foundational IP was developed by CEO Jerome Fox's research group at CU Boulder.

“For the industry, now is the time to solve this problem,” Wil Srubar, an associate professor at CU Boulder and the lead researcher on the project, says in a news release. “We believe that we have one of the best solutions, if not the best solution, for the cement and concrete industry to address its carbon problem.”

The CU Boulder startup, which creates accessible diagnostics for the early detection of disease, will pitch at the Defense TechConnect Innovation Summit for $200K in non-dilutive awards. Challenge finalists represent health and biotech innovation with dual use for civilian and national security applications.

Artimus builds actuator components for industries such as defense, automotive and medical devices. Its proprietary HASEL technology “already has shown incredible potential in many applications,” said CEO Tim Morrissey. “This capital will facilitate optimization of the technology for the best applications.”

SomaLogic, a leader in AI data-driven proteomics technology founded by Professor Larry Gold (MCDB), has entered into an agreement to acquire Palamedrix, Inc.—a move intended to accelerate the SomaScan Platform's utilization in global biopharma and academic markets.